A Bayesian analysis of the VITAL trial: effects of ω-3 fatty acid supplementation on cardiovascular events.
Level 2 - randomized trial
Secondary Bayesian reanalysis of an individual randomized controlled trial incorporating prior trial evidence
PubMed 40032221 · doi:10.1016/j.ajcnut.2025.02.028
What was done
Bayesian reanalysis of the VITAL randomized controlled trial in 25,871 older United States adults followed for a median of 5.3 years to assess 840 mg/day of omega-3 fatty acids (EPA:DHA 1.2:1) for primary prevention. Weibull proportional hazards models with Hamiltonian Monte Carlo sampling were applied to estimate posterior hazard ratios for coronary artery disease, myocardial infarction, composite major cardiovascular events, cardiovascular mortality, all-cause mortality, and stroke using informative priors formulated from Bayesian hierarchical models of previous trials.
What was found
Noninformative priors matched original frequentist results. Informative priors yielded posterior hazard ratios of 0.88 to 0.93 for coronary artery disease and 0.82 to 0.90 for myocardial infarction. Without skepticism in priors, posterior hazard ratios were 0.95 to 0.96 for composite cardiovascular disease, 0.91 to 0.92 for cardiovascular death, and 0.95 to 0.96 for all-cause death, while stroke risk remained unchanged. Primary informed priors showed probabilities of omega-3 efficacy of 99.7% for coronary artery disease, 99.6% for myocardial infarction, 98.4% for composite cardiovascular disease, 99.8% for cardiovascular death, 98.8% for all-cause death, and 33.7% for stroke.
Why it matters
This Bayesian synthesis indicates that when contextualized with prior trial evidence, omega-3 supplementation demonstrates strong probabilistic support for reducing coronary events in a primary prevention population.
Limits
Results depend on the specification and selection of historical trial priors. The abstract does not report credible interval ranges, baseline fish intake or omega-3 status, participant adherence, or adverse event endpoints.
Cited by
- supports The VITAL trial administered 840 milligrams per day of omega-3, which equals one capsule of Lovaza.